Mostrar el registro sencillo del ítem

dc.contributor.authorPalladino, Claudia
dc.contributor.authorEzeonwumelu, Ifeanyi Jude
dc.contributor.authorMate-Cano, Irene 
dc.contributor.authorBorrego, Pedro
dc.contributor.authorArca de Lafuente, Sonia 
dc.contributor.authorTaveira, Nuno
dc.contributor.authorMartinez-Roman, Paula 
dc.contributor.authorResino, Salvador 
dc.contributor.authorBriz, Veronica 
dc.date.accessioned2020-09-14T07:23:01Z
dc.date.available2020-09-14T07:23:01Z
dc.date.issued2020-08-03
dc.identifier.citationSci Rep. 2020 Aug 3;10(1):13024es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11006
dc.description.abstractHepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5-15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important.es_ES
dc.description.sponsorshipThe Instituto de Salud Carlos III (ISCIII) provided financial support by the Grant (CP13/00098, PI15CIII/00031 and PI18CIII/00020 to VB). CP is financed by national funds via FCT through Norma Transitória—DL57/2016/CP1376/CT0004.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEpidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32747734es_ES
dc.format.volume10es_ES
dc.format.number1es_ES
dc.format.page13024es_ES
dc.identifier.doi10.1038/s41598-020-69692-7es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2045-2322es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-020-69692-7es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/CP13/00098es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI15CIII/00031es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI18CIII/00020es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional